Immunophenotyping of serous carcinoma of the female genital tract (Q43997124)

28 November 2017

Immunophenotyping of serous carcinoma of the female genital tract (English)

1 reference

28 November 2017

1 reference

Sharon Nofech-Mozes

1

1 reference

28 November 2017

Mahmoud A Khalifa

2

1 reference

28 November 2017

Nadia Ismiil

3

1 reference

28 November 2017

Reda S Saad

4

1 reference

28 November 2017

Wedad M Hanna

5

1 reference

28 November 2017

Al Covens

6

1 reference

28 November 2017

Zeina Ghorab

7

1 reference

28 November 2017

20 June 2008

1 reference

28 November 2017

1 reference

28 November 2017

21

1 reference

28 November 2017

9

1 reference

28 November 2017

1147-1155

1 reference

https://scigraph.springernature.com/pub.10.1038/modpathol.2008.108

28 November 2017

0 references

cites work

WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.108

Histopathologic grading of ovarian carcinoma: a review and proposal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.108

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.108

Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.108

Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.108

Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.108

Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.108

Old and new perspectives in the management of high-risk, locally advanced or recurrent, and metastatic vulvar cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.108

Heterogeneity of stage IIIA endometrial carcinomas: implications for adjuvant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.108

Current treatment options for endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.108

Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.108

Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.108

Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.108

7 January 2021

Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.108

7 January 2021

WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.108

7 January 2021

WT1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.108

7 January 2021

Wilms Tumor Gene Immunoreactivity in Primary Serous Carcinomas of the Fallopian Tube, Ovary, Endometrium, and Peritoneum

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.108

7 January 2021

Neoadjuvant chemotherapy in uterine papillary serous carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.108

7 January 2021

D2-40 is not a specific marker for cells of mesothelial origin in serous effusions

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.108

7 January 2021

Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.108

7 January 2021

The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.108

7 January 2021

D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.108

7 January 2021

Diagnostic utility of D2-40 and podoplanin in effusion cell blocks

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.108

7 January 2021

Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.108

7 January 2021

Podoplanin: a novel diagnostic immunohistochemical marker

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.108

7 January 2021

Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.108

7 January 2021

Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.108

7 January 2021

h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.108

7 January 2021

Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.108

7 January 2021

A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.108

7 January 2021

10.1038/MODPATHOL.2008.108

Identifiers

DOI

1 reference

Dimensions Publication ID

28 November 2017

0 references

1 reference